TargetMol

Avacopan

Product Code:
 
TAR-T8223
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T8223-1mg1mg£179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8223-2mg2mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8223-5mg5mg£310.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8223-10mg10mg£422.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8223-1mL1 mL * 10 mM (in DMSO)£495.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8223-25mg25mg£591.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8223-50mg50mg£811.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Avacopan is an orally administered small-molecule C5aR ( IC50 : 0.1 nM.)antagonist that blocks the effects of C5a and prevents the development of GN induced by anti-myeloperoxidase antibodies in a murine model of AAV.
CAS:
1346623-17-3
Formula:
C33H35F4N3O2
Molecular Weight:
581.656
Pathway:
Immunology/Inflammation
Purity:
0.999
SMILES:
Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F
Target:
Complement System

References

Gonz?lez?del?Barrio L, P?rez?Al?s L, Cyranka L, et al.MAP?2: CD55 chimeric construct effectively modulates complement activation.The FASEB Journal.2023, 37(11): e23256. Jayne D R W , Bruchfeld A N , Harper L , et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis[J]. Journal of the American Society of Nephrology, 2017:ASN.2016111179. Bekker P, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One. 2016 Oct 21;11(10):e0164646.